Tag Archives: Forbes

The Perfect Close

72263479

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?

TheHill

Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several of the arguments frequently made in recent debates about the price and value of innovative medicines. Philipson argues that physicians are often self-interested as buyers when complaining about drug prices, and often fail to understand the broader economic context in which drug pricing decisions must be made: “Just as you wouldn’t let a financial planner perform cancer surgery, we shouldn’t Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Op-Ed in Forbes on the Threat to Philanthropy

lab_tech02

This week, Howard Husock extols the benefits of venture philanthropy through this Forbes op-ed. In the op-ed, Husock points out that private entities conduct a significant portion of applied research toward new drug development as referenced in this 2008 Manhattan Institute paper, “The Truth About Drug Innovation”, co-authored by two researchers from the Tufts University Center for the Study of Drug Development, and Institute Fellow Benjamin Zycher: “. . .among. . . thirty-five drugs and Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Forbes profiles a medical miracle and the value of cures

kids

This week, Forbes’ Matthew Herper wrote a moving story about a girl who is a medical miracle at only 5-years-old. When Evie Elsaesser was born, she was only expected to live a few hours as her bones were soft and un-calcified. Shortly afterwards, Evie was enrolled in a clinical trial for a drug that replaced the bone-forming enzyme that she was missing. While she suffered from side effects and endured a long road to being Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,